Its share price fell almost 2% yesterday. 

For context, the S&P/ASX 200 Index (ASX: XJO) gained nearly 1%. 

Vitrafy Life Sciences develops a range of proprietary smart cryopreservation hardware devices along with Lifechain – an integrated, cloud-based software platform, to provide a complete, vertically integrated cryopreservation solution to retain the quality of cryopreserved biomaterials.

The company released FY26 Half Year Results that included: 

• Underlying Operating Loss of.-$7.5m
• Operating Cash Outflow of $6.6m v -$4.0m PcP. 
• Cash and cash equivalents ended the period at $22.8m v $29.5m at FY25

Despite yesterday's dip, the share price remains up more than 26% year to date. 

Following its earnings results, the team at Bell Potter released updated guidance on this ASX healthcare stock. 

Here is what the broker had to say. 

Commercial visibility 

Bell Potter acknowledged in its report that currently, most of this ASX healthcare stock's income comes from government R&D incentives and grants, not from selling products.

However, this is expected to change over time as the company starts selling its technology commercially.

Importantly, it has signed its first major commercial agreement with IMV Technologies.

This deal is important because it validates Vitrafy Life Sciences' technology and could lead to very large future revenue (over US$100m per year if widely adopted).

It's important for prospective investors to be aware there is still risk, because the agreement needs to be expanded into a long-term deal.

If the partnership succeeds, it could be a turning point for the company.

Execution risk remains in moving to the long-term agreement, but assuming the partnership is consummated, the IMV partnership may prove to be the game changer the market is seeking. We assume a c.12% penetration across bovine / porcine segments (FY30e).

Upside remains in tact 

Bell Potter has maintained its speculative buy recommendation for this ASX healthcare stock. 

The broker has a price target of $2.25 on Vitrafy Life Sciences. 

From yesterday's closing price of $1.62, this indicates an upside of 38.89%. 

Bell Potter said beyond the IMV partnership, this ASX healthcare stocks' share price could be boosted by positive results from its Phase 2 US military trial, FDA approval of its Guardion medical device, and progress in commercialising its cryopreservation technology for Cell & Gene Therapy.

These events would signal that the technology is working, approved, and starting to generate real commercial interest.

The post Why this ASX healthcare stock is a speculative buy appeared first on The Motley Fool Australia.

It is an Australian innovator in cryopreservation solutions. 

It develops a range of proprietary smart cryopreservation hardware devices along with Lifechain – an integrated, cloud-based software platform, to provide a complete, vertically integrated cryopreservation solution to retain the quality of cryopreserved biomaterials. 

This ASX healthcare stock lost more than 5% in yesterday's trading after the company released its quarterly activities report.

However a new report from broker Bell Potter suggests it could be an undervalued ASX healthcare stock with plenty of upside. 

2Q26 Result

In yesterday's report, the company released financial information. 

It reported improved operating cash flow in 2Q26 with a net outflow of approximately $2.9m.

This was down from roughly $3.7m in 1Q26.

Cash costs increased 47% YoY to $5.0m.

The improvement in cash flows reflected the receipt of $1.8m in grant funding as part of a $4.8m Industry Growth Program grant to commercialise cryopreservation technology.

The $10m the Company had on term deposit rolled over during the quarter.

Across the balance of FY26, average quarterly cash costs are expected to increase around 10-15% in the current half, coinciding with the Company's investment in the ramp up of key regulatory testing work for medical device registration, expansion of the commercial team in the US and investment in an initial fleet of devices to meet anticipated demand.

Investors largely rotated out of the stock based on this report, as this ASX healthcare stock fell 5.66% on Thursday.

Opportunity knocks for this ASX healthcare stock

After yesterday's stock price fall, new analysis from Bell Potter indicates the stock could be significantly undervalued.

The broker said the strategic collaboration with global animal reproduction leader IMV Technologies (over 500m inseminations annually) opens a potential $100m+ managed services opportunity at full penetration across IMV's ~1,200 collection centres. 

The 12-month co-development agreement is expected to deliver ~$0.93m in revenue through CY26 and positions VFY for a longer-term partnership while accelerating animal market progress and allowing greater focus on the North American human health market.

The maiden commercial agreement with IMV appears quite prospective and marks the beginning of commercial visibility into VFY's future.

The broker has a speculative buy rating on this ASX healthcare stock. 

It also upgraded its price target to $2.28 (previously $2.10). 

From yesterday's closing price, this indicates an upside of 30.29%. 

The post This broker just upgraded this ASX healthcare stock and is predicting 30% upside appeared first on The Motley Fool Australia.